stoxline Quote Chart Rank Option Currency Glossary
  
Neurocrine Biosciences, Inc. (NBIX)
140.48  1.08 (0.77%)    05-28 16:00
Open: 140.75
High: 141.725
Volume: 561,119
  
Pre. Close: 139.4
Low: 139.07
Market Cap: 14,137(M)
Technical analysis
2024-05-28 4:54:38 PM
Short term     
Mid term     
Targets 6-month :  170.27 1-year :  198.87
Resists First :  145.77 Second :  170.27
Pivot price 140.09
Supports First :  139 Second :  134.8
MAs MA(5) :  140.07 MA(20) :  140.21
MA(100) :  137.38 MA(250) :  119.89
MACD MACD :  0.6 Signal :  0.7
%K %D K(14,3) :  48.4 D(3) :  47.8
RSI RSI(14): 52.6
52-week High :  148.36 Low :  89.19
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ NBIX ] has closed below upper band by 45.0%. Bollinger Bands are 32.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 141.85 - 142.85 142.85 - 143.62
Low: 137.19 - 138.26 138.26 - 139.08
Close: 139.1 - 140.74 140.74 - 142.01
Company Description

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Headline News

Wed, 29 May 2024
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Increased to $193.00 by Analysts at UBS Group - Defense World

Tue, 28 May 2024
Neurocrine Biosciences CEO Gorman stepping down in October - Seeking Alpha

Tue, 28 May 2024
Neurocrine Biosciences (NBIX) Announces CEO Change - StreetInsider.com

Tue, 28 May 2024
Neurocrine Biosciences Announces CEO Succession Plan - PR Newswire

Tue, 28 May 2024
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $193.00 - MarketBeat

Tue, 28 May 2024
Key Takeaways From Neurocrine Biosciences Analyst Ratings - Neurocrine Biosciences (NASDAQ:NBIX) - Benzinga

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 101 (M)
Shares Float 99 (M)
Held by Insiders 1 (%)
Held by Institutions 95.8 (%)
Shares Short 1,830 (K)
Shares Short P.Month 2,430 (K)
Stock Financials
EPS 3.68
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 23.71
Profit Margin 18.6 %
Operating Margin 20.4 %
Return on Assets (ttm) 10 %
Return on Equity (ttm) 18.1 %
Qtrly Rev. Growth 22.6 %
Gross Profit (p.s.) 0
Sales Per Share 19.67
EBITDA (p.s.) 4.89
Qtrly Earnings Growth 0 %
Operating Cash Flow 645 (M)
Levered Free Cash Flow 719 (M)
Stock Valuations
PE Ratio 38.17
PEG Ratio 1.8
Price to Book value 5.92
Price to Sales 7.14
Price to Cash Flow 21.9
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android